dc.contributor.author | Soyer, N. | |
dc.contributor.author | Ali, R. | |
dc.contributor.author | Turgut, M. | |
dc.contributor.author | Haznedaroğlu, İ.C. | |
dc.contributor.author | Yilmaz, F. | |
dc.contributor.author | Aydoğdu, İ. | |
dc.contributor.author | Pir, A. | |
dc.contributor.author | Karakuş, V. | |
dc.contributor.author | Özgür, G. | |
dc.contributor.author | Kiş, C. | |
dc.contributor.author | Ceran, F. | |
dc.contributor.author | Ilhan, G. | |
dc.contributor.author | Özkan, M. | |
dc.contributor.author | Aslaner, M. | |
dc.contributor.author | Ince, İ. | |
dc.contributor.author | Yavaşoğlu, İ. | |
dc.contributor.author | Gediz, F. | |
dc.contributor.author | Sönmez, M. | |
dc.contributor.author | Güvenç, B. | |
dc.contributor.author | Özet, G. | |
dc.contributor.author | Kaya, E. | |
dc.contributor.author | Vural, F. | |
dc.contributor.author | Şahin, F. | |
dc.contributor.author | Töbü, M. | |
dc.contributor.author | Durusoy, R. | |
dc.contributor.author | Saydam, G. | |
dc.date.accessioned | 2022-10-06T12:50:25Z | |
dc.date.available | 2022-10-06T12:50:25Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 13000144 (ISSN) | |
dc.identifier.uri | http://hdl.handle.net/11616/71798 | |
dc.description.abstract | Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment. © TÜBİTAK. | |
dc.source | Turkish Journal of Medical Sciences | |
dc.title | Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in turkey |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |